Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms - 18/11/20
, Jianfeng Sun b, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 19 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Ginsenosides have a great potential in Mets and CVDs treatment. |
• | This review comprehensively clarifies the molecular mechanism in the treatment of ginsenosides on Mets and CVDs. |
• | This review summarizes the clinic trials of ginsenosides on Mets and CVDs. |
• | This review prospects the future development direction of ginsenosides. |
Abstract |
Epidemiological studies showed that the metabolic syndromes (MetS) and cardiovascular diseases (CVDs) are responsible for a serious threat to human health worldwide. MetS is a syndromes characterized by fat metabolism disorder, obesity, diabetes, insulin resistance and other risk factors, which increases the risk of CVDs initiation and development. Although certain drugs play a role in lowering blood sugar and lipid, some side effects also occur. Considering the multiple pathogenesis, a great deal of natural products have been attempted to treat metabolic syndromes. Ginsenosides, as the active components isolated from Panax ginseng C.A.Mey, have been reported to have therapeutic effects on MetS and CVDs, of which pharmacological mechanisms were further studied as well. This review aims to systematically summarize current pharmacological effects of ginsenosides on MetS and CVDs, potential mechanisms and clinic trials, which will greatly contribute to the development of potential agents for related disease treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations : MetS, CVDs, DIO, HFD, PPAR γ, C/EBPs, FABP4, FAS, AMPK, ROS, WAT, TNF-α, IL-6, IL-1β, DM, T1DM, T2DM, IR, STZ, HFHS, SGLT1, GLUT2, ER, JNKs, NO, ERKs, MAPKs, G6Pase, GLP1, VEGF, DR, DN, COX-1, Nrf2, HO-1, DCM, NAFLD, OLETF, Sirt1, Con A, TG, VSMC, H/R, HF, MI, I/R, ATF6, IRE1, CHOP, cTnl, GSK-3β, IGF-1, IGF1R, BATs, NADPH, Jak2, STAT3, SREBP-1c, ACC, HSL, PLIN1, UCP1, PRDM16, CPT1, SHP
Chemical compounds studied in this article : Ginsenoside Rb1 (PubChem CID:9898279), Ginsenoside Rb2 (PubChem CID: 6917976), Ginsenoside Rb3 (PubChem CID: 12912363), Ginsenoside Rg1 (PubChem CID:441923), Ginsenoside Rg2 (PubChem CID: 21599924), Ginsenoside Rg3 (PubChem CID: 9918693), Ginsenoside Rd (PubChem CID:24721561), Ginsenoside Re (PubChem CID: 441921), Ginsenoside compound K (PubChem CID: 9852086)
Keywords : Metabolic syndrome, Cardiovascular diseases, Ginsenosides, Signaling pathways, Mechanism
Plan
Vol 132
Article 110915- décembre 2020 Retour au numéro
Article précédent
- Development of small molecule inhibitors/agonists targeting STING for disease
- Kaifeng Liu, Yongqi Lan, Xiaoling Li, Mingyue Li, Liao Cui, Hui Luo, Lianxiang Luo
- Sagittaria sagittifolia polysaccharide interferes with arachidonic acid metabolism in non-alcoholic fatty liver disease mice via Nrf2/HO-1 signaling pathway
- Xinqi Deng, Xiuhui Ke, Yibo Tang, Weizao Luo, Ruijuan Dong, Dongyu Ge, Li Han, Yajie Yang, Hongshuang Liu, Tuerxun Reyila, Yan Liao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?